Home
Resources
Diseases
COVID-19
Ebola
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hepatitis B birth dose vaccines
Hexavalent vaccines
HPV vaccines
Malaria vaccines
Measles containing vaccines
PCV vaccines
RSV vaccines
Typhoid Conjugate Vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
RSV
RSV (Respiratory syncytial virus)
Type of publications
Guidelines (1)
NITAG documentation (36)
SAGE documentation (4)
Systematic reviews (SYSVAC) (30)
Regions
Africa (2)
Americas (19)
Europe (13)
Western Pacific (3)
Diseases
RSV (Respiratory syncytial virus) (71)
Cholera (1)
COVID-19 (8)
Dengue (1)
Diphtheria (1)
Ebola (1)
Haemophilus influenzae type B (1)
Hepatitis B (1)
Hepatitis E (1)
Herpes zoster (1)
Influenza (5)
Measles (2)
Mpox (3)
Pertussis (2)
Pneumococcal disease (4)
Poliomyelitis (3)
Rubella (1)
Tetanus (1)
Tuberculosis (1)
Show more
Methodological quality (AMSTAR 2)
High (2)
Moderate (2)
Low (7)
Critically low (12)
Not applicable (7)
71 results found
2025
Use of the bivalent respiratory syncytial virus (RSV) vaccine (Abrysvo™, Pfizer) during pregnancy for the prevention of RSV–associated lower respiratory tract disease in Infants
2025
Update to the document “Evaluation of RSV vaccination in the adult population”
2025
∙
National Advisory Group on Immunisation (NAGI)
RSV vaccination recommendation during pregnancy
2025
∙
ATAGI
Summary of the ATAGI 116th meeting, 15 October 2025
2025
∙
NIAC
Updated recommendations for vaccination against respiratory syncytial virus in older adults
2025
∙
ATAGI
ATAGI statement on RSV administration errors
2025
RSV immunisation programme: JCVI advice, 16 July 2025
2025
∙
WHO
WHO position paper on Respiratory Syncytial Virus (RSV)
2025
∙
Jefferson Jones
Proposed clinical considerations for clesrovimab
2025
∙
Danielle Moulia
Evidence to Recommendations Framework: Clesrovimab
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register
